Get the Stockscreener App
168.76
1.84%
-3.17
After Hours:
168.16
-0.60
-0.36%
Belite Bio Inc Adr stock is traded at $168.76, with a volume of 102.73K.
It is down -1.84% in the last 24 hours and up +2.83% over the past month.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.
See More
Previous Close:
$171.93
Open:
$171.04
24h Volume:
102.73K
Relative Volume:
0.54
Market Cap:
$6.74B
Revenue:
-
Net Income/Loss:
$-77.61M
P/E Ratio:
-73.44
EPS:
-2.2979
Net Cash Flow:
-
1W Performance:
-5.58%
1M Performance:
+2.83%
6M Performance:
+107.68%
1Y Performance:
+186.62%
1-Day Range:
$167.00
$171.20
1-Week Range:
$167.00
$183.67
52-Week Range:
$53.59
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
168.76 | 6.87B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-26 | Initiated | BofA Securities | Buy |
| Jan-06-26 | Initiated | Morgan Stanley | Overweight |
| Dec-02-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-24-25 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-20-25 | Initiated | Mizuho | Neutral |
| Dec-14-23 | Initiated | Maxim Group | Buy |
| Jul-28-23 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-23 | Initiated | SVB Securities | Outperform |
| Aug-01-22 | Initiated | H.C. Wainwright | Buy |
| Jul-01-22 | Initiated | The Benchmark Company | Buy |
View All
Belite Bio Inc Adr Stock (BLTE) Latest News
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Belite Bio CEO Lin Yu-Hsin sells $1.66m in shares - Investing.com India
Belite Bio (BLTE) CEO Lin Yu-Hsin sells 9,200 ADS in planned trade - Stock Titan
Belite Bio (BLTE) director sells 1,100 ADS via Rule 10b5-1 plan - Stock Titan
Belite Bio (BLTE) CFO sells 6,200 ADS under Rule 10b5-1 plan - Stock Titan
H.C. Wainwright reiterates Belite Bio stock rating at buy By Investing.com - Investing.com Australia
Belite Bio (BLTE) Eps Diluted (TTM) - Zacks Investment Research
BLTE (NASDAQ) files Form 144 listing ADS sales and vesting activity - Stock Titan
[144] BELITE BIO, INC SEC Filing - Stock Titan
Belite Bio (NASDAQ: BLTE) lists 1,400 and 8,796 shares from option exercises - Stock Titan
(BLTE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Benchmark reaffirms Belite Bio stock rating on cash position, trial progress - Investing.com Canada
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Belite Bio (NASDAQ:BLTE) Rating Increased to Hold at Wall Street Zen - Defense World
Belite Bio Posts 2025 Form 20-F Annual Report Online as Late-Stage Retinal Drug Trials Advance - tipranks.com
Belite Bio (BLTE) Is Up 7.9% After Phase 3 DRAGON Win And $402M OfferingHas The Bull Case Changed? - Sahm
Mizuho reiterates Belite Bio stock rating on NDA timeline update - Investing.com
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO now holds 289,736 vested option shares - Stock Titan
Belite Bio (BLTE) CSO gains 144,868-share option vesting - Stock Titan
Belite Bio Jumps on Drug Hopes and Analyst Boost - TipRanks
Belite Bio Faces Higher Compliance Burden as It Becomes a Large Accelerated Filer, Raising Costs and Operational Risk - TipRanks
Belite Bio, Inc. ADR Shares Surge on Drug Progress - tipranks.com
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website - The Manila Times
Belite Bio (NASDAQ: BLTE) posts 2025 Form 20-F and audited results online - Stock Titan
Belite Bio (BLTE) 2025 20-F: Tinlarebant NDA plan and rising losses - stocktitan.net
Stargardt Disease Pipeline 2026: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - Barchart.com
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Grows By 25.1% - MarketBeat
(BLTE) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Belite Bio (NASDAQ:BLTE) Stock Rating Lowered by Wall Street Zen - MarketBeat
Belite Bio (NASDAQ: BLTE) CMO details option grants and indirect holdings - Stock Titan
Belite Bio (NASDAQ: BLTE) CSO details stock options and share stakes - Stock Titan
Belite Bio (BLTE) CFO Chuang Hao-Yuan details options and shares in Form 3 - Stock Titan
Belite Bio (NASDAQ: BLTE) director discloses 400 ADS position - Stock Titan
BELITE BIO (BLTE) director Longo reports 110,000-share stock option holdings - Stock Titan
Belite Bio (BLTE) director Lu Ita reports 110,000-share option stake - Stock Titan
Belite Bio (BLTE) director details stock option grants and vesting - Stock Titan
Belite Bio (BLTE) CEO Lin Yu-Hsin details option and share holdings - Stock Titan
Belite Bio (BLTE) director reports initial ADS and ordinary share stakes - Stock Titan
(BLTE) Risk Channels and Responsive Allocation - Stock Traders Daily
Belite Bio Stock Stumbles as Traders Flee Rally - TipRanks
Short Interest in Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Expands By 16.2% - MarketBeat
Belite Bio Details Phase 3 DRAGON Win as Tinlarebant Cuts Stargardt Lesion Growth 36% at Conference - Defense World
Mizuho reiterates Belite Bio stock rating on NDA timeline update By Investing.com - Investing.com Nigeria
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
H.C. Wainwright raises Belite Bio stock price target on NDA timeline - Investing.com Nigeria
Belite Bio Eyes 2027 Launch After Pivotal Win - TipRanks
Belite Bio at Leerink Conference: Tinlarebant’s Promising Trials - Investing.com
Belite Bio (BLTE) to Release Earnings on Monday - MarketBeat
What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World
Belite Bio Inc Adr Stock (BLTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.69%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):